Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy

Kenta Yoshiura, Takashi Nakaoka, Toshihide Nishishita, Katsuaki Sato, Akifumi Yamamoto, Shinji Shimada, Toshiaki Saida, Yutaka Kawakami, Tsuneo A. Takahashi, Hiroyuki Fukuda, Shinobu Imajoh-Ohmi, Naoki Oyaizu, Naohide Yamashita

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction.

Original languageEnglish
Pages (from-to)8201-8207
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number22
DOIs
Publication statusPublished - 2005 Nov 15

Fingerprint

Carbonic Anhydrase II
Cell- and Tissue-Based Therapy
Dendritic Cells
Endothelium
Antigens
Neoplasms
Neoplasm Antigens
Antibodies
Melanoma-Specific Antigens
Proteins
Kidney Neoplasms
Esophageal Neoplasms
Serum
Immunotherapy
Electrophoresis
Veins
Cultured Cells
Melanoma
Lung Neoplasms
Mass Spectrometry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yoshiura, K., Nakaoka, T., Nishishita, T., Sato, K., Yamamoto, A., Shimada, S., ... Yamashita, N. (2005). Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. Clinical Cancer Research, 11(22), 8201-8207. https://doi.org/10.1158/1078-0432.CCR-05-0816

Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. / Yoshiura, Kenta; Nakaoka, Takashi; Nishishita, Toshihide; Sato, Katsuaki; Yamamoto, Akifumi; Shimada, Shinji; Saida, Toshiaki; Kawakami, Yutaka; Takahashi, Tsuneo A.; Fukuda, Hiroyuki; Imajoh-Ohmi, Shinobu; Oyaizu, Naoki; Yamashita, Naohide.

In: Clinical Cancer Research, Vol. 11, No. 22, 15.11.2005, p. 8201-8207.

Research output: Contribution to journalArticle

Yoshiura, K, Nakaoka, T, Nishishita, T, Sato, K, Yamamoto, A, Shimada, S, Saida, T, Kawakami, Y, Takahashi, TA, Fukuda, H, Imajoh-Ohmi, S, Oyaizu, N & Yamashita, N 2005, 'Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy', Clinical Cancer Research, vol. 11, no. 22, pp. 8201-8207. https://doi.org/10.1158/1078-0432.CCR-05-0816
Yoshiura, Kenta ; Nakaoka, Takashi ; Nishishita, Toshihide ; Sato, Katsuaki ; Yamamoto, Akifumi ; Shimada, Shinji ; Saida, Toshiaki ; Kawakami, Yutaka ; Takahashi, Tsuneo A. ; Fukuda, Hiroyuki ; Imajoh-Ohmi, Shinobu ; Oyaizu, Naoki ; Yamashita, Naohide. / Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 22. pp. 8201-8207.
@article{4c811c168ff844fba34cd07143f1a9c6,
title = "Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy",
abstract = "Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction.",
author = "Kenta Yoshiura and Takashi Nakaoka and Toshihide Nishishita and Katsuaki Sato and Akifumi Yamamoto and Shinji Shimada and Toshiaki Saida and Yutaka Kawakami and Takahashi, {Tsuneo A.} and Hiroyuki Fukuda and Shinobu Imajoh-Ohmi and Naoki Oyaizu and Naohide Yamashita",
year = "2005",
month = "11",
day = "15",
doi = "10.1158/1078-0432.CCR-05-0816",
language = "English",
volume = "11",
pages = "8201--8207",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy

AU - Yoshiura, Kenta

AU - Nakaoka, Takashi

AU - Nishishita, Toshihide

AU - Sato, Katsuaki

AU - Yamamoto, Akifumi

AU - Shimada, Shinji

AU - Saida, Toshiaki

AU - Kawakami, Yutaka

AU - Takahashi, Tsuneo A.

AU - Fukuda, Hiroyuki

AU - Imajoh-Ohmi, Shinobu

AU - Oyaizu, Naoki

AU - Yamashita, Naohide

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction.

AB - Tumor-associated antigens are promising candidates as target molecules for immunotherapy and a wide variety of tumor-associated antigens have been discovered through the presence of serum antibodies in cancer patients. We previously conducted dendritic cell therapy on 10 malignant melanoma patients and shrinkage or disappearance of metastatic tumors with massive necrosis occurred in two patients. In this study, we found a 29-kDa protein against which antibody was elicited by dendritic cell therapy in one of the two patients. Matrix-assisted laser desorption ionization-time of flight/mass spectrometry analysis of the protein isolated by two-dimensional electrophoresis combined with Western blots revealed that the 29-kDa protein was carbonic anhydrase II (CA-II). Immunohistochemistry of the tumors and normal tissues showed that CA-II was expressed in the tumor vessel but not in normal vessel endothelium. CA-II expression in tumor endothelium was observed as well in other cancers including esophageal, renal, and lung cancers. In an in vitro angiogenesis model, CA-II expression of normal human vein endothelial cells was significantly up-regulated when cells were cultured in the acidic and hypoxic conditions indicative of a tumor environment. These findings suggest that CA-II is a tumor vessel endothelium-associated antigen in melanoma and other cancers, and elicitation of serum anti-CA-II antibody by dendritic cell therapy may be associated with good clinical outcome including tumor reduction.

UR - http://www.scopus.com/inward/record.url?scp=28144440647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28144440647&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0816

DO - 10.1158/1078-0432.CCR-05-0816

M3 - Article

VL - 11

SP - 8201

EP - 8207

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 22

ER -